July 13-14, 2018 Phoenicia Hotel, Beirut - Lebanon

Transcription

1 Under the Patronage of the President of the Lebanese Order of Physicians - Beirut Prof. Raymond Sayegh July 13-14, 2018 Phoenicia Hotel, Beirut - Lebanon Organized by The Lebanese Society of Medical Oncology Licensed by The American Society of Clinical Oncology Endorsed by The Arab Medical Association Against Cancer

2 Dear Colleagues, It gives me great pleasure to welcome you to The 13 th Annual Best of ASCO meeting 2018 organized by the Lebanese Society of Medical Oncology LSMO under the license of ASCO, which will be held on July 13-14, 2018 at Phoenicia Hotel, Beirut Lebanon. This year s congress will feature up-to-date information on several topics in the field of Oncology and malignant hematology. The congress will bring together several experts in the field and will be widely attended, locally and regionally. We expect to host over 300 oncology physicians, highly renowned speakers who will cover a wide range of exciting and timely topics in the different disciplines of Oncology, and host attendees coming from all over the Middle East, Europe, and the United States. As usual, and as per ASCO regulations, the Planning Committee included the most relevant abstracts selected by ASCO s Best of ASCO committee and in addition to two Education Sessions. Your participation and support are essential where only here you can customize a unique educational experience, selected from an unparalleled array of topics, learning styles, and expert viewpoints. Best of ASCO 2018 will provide a good networking venue for people to get to know each other better and the experiences you share with colleagues, your challenging questions for our presenters and your dedication to our mission all contribute to an outstanding event. I wish you all a productive meeting and memorable time in Lebanon. Nizar Bitar, MD Chair of the Best of ASCO Nagi El Saghir, MD Co-Chair of the Best of ASCO

3 13 th Best of ASCO Lebanon July 13-14, Phoenicia Hotel, Beirut - Lebanon Organized by LSMO (Lebanese Society of Medical Oncology) Licensed by ASCO (American Society of Clinical Oncology) Endorsed by AMAAC (Arab Medical Association Against Cancer) Chairs: Nizar Bitar, MD Chair Nagi El Saghir, MD, FACP, FASCO Co-Chair Planning Committee: Nizar Bitar, MD Nagi El Saghir, MD, FACP, FASCO Joseph Makdessi, MD Fadi Karak, MD Arafat Tfayli, MD Rita Murr, MD Sami El Khatib, MD Organizing Committee / LSMO Board Nizar Bitar, MD President Roger Khater, MD President Elect Oussama Jradi, MD General Secretary Therese Abou Nasr, MD Treasurer Naji Amro, MD Member Mohammad Haidar, MD Member Walid Moukadem, MD Member Rita Murr, MD Member Hanane Yassine, MD Member

4 Guest Speaker Ghassan Abou-Alfa, MD USA Sana Al-Sukhun, MD Jordan Hazem Assi, MD Lebanon Rita Assi, MD Lebanon Ahmad Awada, MD Belgium Carlos Barrios, MD Brazil Nizar Bitar, MD Lebanon Etienne Brain, MD France Jean El Cheikh, MD Lebanon Imane El Dika, MD Lebanon Nagi El Saghir, MD Lebanon Marwan Ghosn, MD Lebanon Mohamad Haidar, MD Lebanon Ahmad Ibrahim, MD Lebanon Khaled Ibrahim, MD Lebanon Faek Jamali, MD Lebanon Joseph Kattan, MD Lebanon Fadlo Khuri, MD Lebanon Hampig Kourie, MD Lebanon Joseph Makdessi, MD Lebanon Deborah Mukherji, MD Lebanon Fadi Nasr, MD Lebanon Ghazi Nsouli, MD Lebanon Eileen O Reilly, MD USA Ziad Salem, MD Lebanon Muhieddine Seoud, MD Lebanon Issam Shehade, MD Lebanon Arafat Tfayli, MD Lebanon Ahmad Younes, MD Lebanon Ali Youssef, MD Lebanon

5 Friday July 13, :00 REGISTRATION 09:00 Welcome Note Nizar Bitar, MD, President, LSMO Chair, Best of ASCO Lebanon :00-09:30 Hematologic Malignancies Leukemia, Myelodysplastic Syndromes, and Allotransplant Speakers: Rita Assi, MD - Ziad Salem, MD Chairs: Sami Khatib, MD - Ahmad Ibrahim, MD Abstract 103: Impact of Next-Generation Sequencing (NGS) on Treatment Selection in Acute Myeloid Leukemia (AML). Rita Assi Presented by Rita Assi Abstract 7000: Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study. Daniel Pollyea Presented by Rita Assi Abstract 7004: Moxetumomab Pasudotox in Heavily Pretreated Patients with Relapsed/ Refractory Hairy Cell Leukemia: Results of a Pivotal International Study. Robert Kreitman Presented by Ziad Salem Abstract 7010: Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML). Courtney Dinardo Presented by Ziad Salem 09:30-10:00 Hematologic Malignancies Lymphoma and Chronic Lymphocytic Lymphoma Speakers: Nizar Bitar, MD - Jean El-Cheikh, MD - Ahmad Ibrahim, MD Chairs: Mohamad Haidar, MD - Jean El-Cheikh, MD - Hassan Kanaan, MD Abstract 7500: RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. Nathan Fowler Presented by Nizar Bitar Abstract 7501: Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM). Roger Owen Presented by Nizar Bitar Abstract 7502: Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). William Wierda Presented by Jean El-Cheikh Abstract 7505: Updated Safety & Long Term Clinical Outcomes in TRANSCEND NHL 001, Pivotal Trial of Lisocabtagene Maraleucel (JCAR017) in R/R Aggressive NHL. Jeremy Abramson Presented by Ahmad Ibrahim

6 Friday July 13, :00-10:30 Hematologic Malignancies Plasma Cell Dyscrasia Speakers: Khaled Ibrahim, MD - Issam Shehade, MD - Ali Youssef, MD Chairs: Rahif Jalloul, MD - Hassan Ghazal, MD Abstract 8000: Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W. Maria-Victoria Mateos Presented by Khaled Ibrahim Abstract 8003: Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's Macroglobulinemia. Meletios Dimopoulos Presented by Issam Shehade Abstract 8004: Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Luciano Costa Presented by Khaled Ibrahim Abstract 8008: FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (iraes) and response. Aviva Krauss Presented by Ali Youssef 10:30-11:00 Coffee Break 11:00-11:45 Gastrointestinal (Colorectal) Cancer Speakers: Imane El Dika, MD - Eileen O Reilly, MD - Ghazi Nsouli, MD - Ghassan Abou-Alfa, MD Chairs: Sally Tamraz, MD - Mirna El Hajj, MD Abstract 3501: Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. Yong Sang Hong Presented by Imane El Dika Abstract LBA3503: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. François Quenet Presented by Eileen O Reilly Abstract 3505: First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mcrc): The VALENTINO study. Filippo Pietrantonio Presented by Ghazi Nsouli Abstract 3514: KEYNOTE-164: Pembrolizumab for Patients With Advanced Microsatellite Instability High (MSI-H) Colorectal Cancer. Dung Le Presented by Ghassan Abou-Alfa

7 Friday July 13, :45-12:30 Gastrointestinal (Noncolorectal) Cancer Speakers: Eileen O Reilly, MD - Deborah Mukherji, MD - Ghassan Abou-Alfa, MD Chairs: Abdel Fattah Kheir, MD - Oussama Safar, MD Abstract LBA4001: Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mfolfirinox versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Thierry Conroy Presented by Eileen O Reilly Abstract 4004: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Pamela Kunz Presented by Eileen O Reilly Abstract LBA4008: Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial. Janusz Jankowski Presented by Deborah Mukherji Abstract 4019: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial. Ghassan Abou-Alfa Presented by Ghassan Abou-Alfa 12:30-13:00 Patient and Survivor Care Speakers: Etienne Brain, MD - Ahmad Younes, MD Chairs: Haifa Dbouk, MD - Fadi Farhat, MD - Amal Nasser, MD Abstract 10000: Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Sherry Shen Presented by Etienne Brain Abstract 10001: The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: A randomized clinical trial. Jun Mao Presented by Etienne Brain Abstract LBA10003: Improving Communication with Older Patients with Cancer using Geriatric Assessment (GA): A University of Rochester NCI Community Oncology Research Program (NCORP) Cluster Randomized Controlled Trial (CRCT). Supriya Mohile Presented by Etienne Brain Abstract 10005: Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer. Charn-Xin Fuh Presented by Ahmad Younes 13:00-14:00 Lunch Break

8 Friday July 13, :00-14:45 Breast Cancer Local / Regional / Adjuvant Speakers: Etienne Brain, MD - Sanaa Al-Sukhun, MD - Ahmad Awada, MD Chairs: Christina Khater, MD - Joseph Makdessi, MD Abstract LBA1: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score. Joseph Sparano Presented by Etienne Brain Abstract 104: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Sibylle Loibl Presented by Etienne Brain Abstract 500: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. Michael Gnant Presented by Sanaa Al-Sukhun Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Helena Earl Presented by Ahmad Awada 14:45-15:30 Breast Cancer Metastatic Speakers: Nagi El Saghir, MD - Carlos Barrios, MD - Etienne Brain, MD - Ahmad Awada, MD Chairs: Rita Murr, MD - Ali Mounzer, MD - Mouin Mubarak, MD - Adel Tabchi, MD Abstract 1000: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2 ) advanced breast cancer (ABC): Results from MONALEESA-3. Dennis Slamon Presented by Nagi El Saghir Abstract 1005: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study. Guy Jerusalem Presented by Carlos Barrios Abstract 1006: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. Jose Baselga Presented by Etienne Brain Abstract 1007: AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Peter Schmid Presented by Ahmad Awada

9 Friday July 13, :30-16:00 Coffee Break 16:00-17:00 Melanoma / Skin Cancer Speakers: Ahmad Awada, MD - Faek Jamali, MD - Hazem Assi, MD - Fadi Nasr, MD Chairs: Hazem Assi, MD - Mohamad Yassine, MD Abstract 108: Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. Georgina Long Presented by Ahmad Awada Abstract 9501: Final analysis of DECOG-SLT trial: No survival benefit for complete lymph node dissection in melanoma patients with positive sentinel node. Ulrike Leiter Presented by Faek Jamali Abstract 9502: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). Jeffrey Weber Presented by Hazem Assi Abstract 9504: Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma. Reinhard Dummer Presented by Fadi Nasr 17:00-17:30 Educational Session Speakers: TBA Chairs: TBA 17:30-18:00 Opening Ceremony Address of the President of Lebanese Society of Medical Oncology and Chair of the Best of ASCO Nizar Bitar, MD Address of the Co-Chair Best of ASCO Nagi El Saghir, MD Address of AMAAC General Secretary Sami Khatib, MD Address of the President of the Lebanese Order of Physicians - Beirut Raymond Sayegh, MD What Can we Learn from the Other Side of the Bed Ghassan Abou-Alfa, MD, MBA

10 Saturday July 14, :00-09:45 Head and Neck Cancer Speakers: Hampig kourie, MD - Georges Farha, MD - Fadlo Khuri, MD - Bassem Youssef, MD Chairs: Roger Moukarbel, MD - Alain Sabri, MD Abstract 6000: Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck. Vijay Patil Presented by Hampig Kourie Abstract 6006: Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced Carryn Anderson Presented by Georges Farha Abstract 6008: Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC). Douglas Adkins Presented by Fadlo Khuri Abstract 6009: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). Sean McBride Presented by Bassem Youssef 09:45-10:30 Lung Cancer Non-Small Cell Local-Regional / Small Cell / Thoracic Cancers Speakers: Adel Tabchi, MD - Ahmad Younes, MD - Fadlo Khuri, MD Chairs: Arafat Tfayli, MD - Walid Moukkadem, MD Abstract 8502: Pragmatic Study of a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resection. Raymond Osarogiagbon Presented by Adel Tabchi Abstract 8503: DREAM: A Phase II study of DuRvalumab with first line chemotherapy in Mesothelioma: First Results. Anna Nowak Presented by Ahmad Younes Abstract 8506: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. Hyun Chung Presented by Fadlo Khuri Abstract 8507: Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, 3rd line small cell lung cancer: results from the Phase 2 TRINITY study. David Carbone Presented by Fadlo Khuri 10:30-11:00 Coffee Break

11 Saturday July 14, :00-11:45 Lung Cancer Non-Small Cell Metastatic Speakers: Arafat Tfayli, MD - Carlos Barrios, MD Chairs: Arafat Tfayli, MD - Nizar Bitar, MD Abstract LBA4: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. Gilberto Lopes Presented by Arafat Tfayli Abstract 105: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC). Luis Paz-Ares Presented by Arafat Tfayli Abstract LBA9000: IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-paclitaxel as 1L Therapy in Advanced Squamous NSCLC. Robert Jotte Presented by Arafat Tfayli Abstract 9001: Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study. Hossein Borghaei Presented by Arafat Tfayli Abstract 9006: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026. Naoki Furuya Presented by Carlos Barrios 11:45-12:30 Genitourinary (Prostate) Cancer Speakers: Mohamad Haidar, MD - Joseph Kattan, MD - Joseph Makdessi, MD Chairs: Deborah Mukherji, MD - Fadi Nasr, MD Abstract 5001: 68Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial. Wolfgang Fendler Presented by Mohamad Haidar Abstract 5000: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial. Pirkko-Liisa Kellokumpu-Lehtinen Presented by Joseph Kattan Abstract 5003: Olaparib combined with abiraterone in patients (pts) with metastatic castrationresistant prostate cancer (mcrpc): A randomized Phase II trial. Noel Clarke Presented by Joseph Kattan Abstract 5007: KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mcrpc). Johann De Bono Presented by Joseph Makdessi

12 Saturday July 14, :30-13:00 Educational Session Speakers: TBA Chairs: TBA 13:00-14:00 Lunch Break 14:00-14:45 Genitourinary (Nonprostate) Cancer Speakers: Deborah Mukherji, MD - Ahmad Awada, MD - Marwan Ghosn, MD Chairs: Joseph Kattan, MD - Maha Manachi, MD Abstract LBA3: CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma-results of a phase III noninferiority trial. Arnaud Mejean Presented by Deborah Mukherji Abstract 4500: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accrcc): results from cohort A of KEYNOTE-427. David McDermott Presented by Ahmad Awada Abstract 4503: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ ) in patients (pts) with metastatic or unresectable urothelial carcinoma (muc) and FGFR alterations (FGFRalt). Arlene Siefker-Radtke Presented by Ahmad Awada Abstract 4511: Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mrcc). Bernard Escudier Presented by Marwan Ghosn 14:45-15:15 Gynecologic Cancer Speakers: Muhieddine Seoud, MD - Hampig Kourie, MD Chairs: Nagi El Saghir, MD - David Atallah, MD - Jihad Ezzedine, MD Abstract 5500: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602. Takashi Onda Presented by Muhieddine Seoud Abstract 5505: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study. Martee Hensley Presented by Muhieddine Seoud Abstract 5506: Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. Sandro Pignata Presented by Muhieddine Seoud Abstract 5508: Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel, Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab. Juliet Wolford Presented by Hampig Kourie

13 Saturday July 14, :15-15:45 Developmental Therapeutics Speaker: Ahmad Awada, MD Chair: Nizar Bitar, MD Abstract 102: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. Alexander Drilon Presented by Ahmad Awada Abstract 3000: ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients (pts) with advanced cancers. Timothy Yap Presented by Ahmad Awada Abstract 3003: Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Refractory Large B Cell Lymphoma. Frederick Locke Presented by Ahmad Awada Abstract 3006: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. Adi Diab Presented by Ahmad Awada 16:00 Adjourn Nagi El Saghir, MD, FACP, FASCO, Co-Chair, Best of ASCO Lebanon

14 Organized by: LEBANON 4 th Floor, Qubic Center Daoud Ammoun Street Horsh Tabet - Sin El Fil P.O. Box: Beirut Tel: /1/2/3 Mobile: UAE DMCC Business Centre Almas Tower Jumeirah Lakes Dubai, United Arab Emirates Unit No: 3820 Mobile: